On Thursday, the European Union published its first draft of a Code of Practice for general purpose AI (GPAI) models. The document, which won’t be finalized until May, lays out guidelines for managing risks — and giving companies a blueprint to comply and avoid hefty penalties.

A first draft of a Code of Practice that will apply to providers of general-purpose AI models under the European Union's AI Act has been published,

The European Union has released the first draft of the general-purpose AI code of practice portion of the AI Act. Read for more.

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatment.

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at slowing cognitive decline in patients. In July, the Amsterdam-based European Medicines Agency (EMA) denied recommending approval of the drug made by Eisai and Biogen because it considered the risks - especially bleeding and swelling in the brain - to be greater than the potential benefits in a broad population.

The European Parliament voted on Thursday for a 12-month delay to the implementation of a law banning the import of commodities linked to deforestation, and adopted a series of amendments to weaken the law itself.

The European Parliament demanded further changes to a landmark law to tackle global deforestation, adding complications to a plan to delay the controversial rules before they take effect later this year.

The European Parliament on Thursday approved a one-year delay on implementing the bloc's sweeping anti-deforestation rules but also voted to loosen some requirements -- raising fresh uncertainty over